StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals, Inc. saw revenue fall 45.5% to $336.11K over fiscal 2025. At the latest close the market valued the company at $20.55M.

Revenue
$336.11K
-45.5% vs. a year earlier
Operating income
-$4.52M
TTM Q3 2026
EPS, diluted
$0.00
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026

Valuation

Market cap
$20.55M
P/E ratio
–
Price to sales
61.15
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$336.11K
Net income
-$4.70M
EPS, diluted
$0.00
Book value per share
-$0.02
Diluted shares
420M

Trading

Previous close
$0.05
Open
$0.05
Day's range
$0.05 – $0.05
Volume
51,200
Average volume (20 days)
67,422

Market cap history

Month-end market cap since 2011, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodPVCTS&P 500DifferencePVCT per yearS&P 500 per year
1 month-11.1%+0.6%−11.7 pts
3 months-19.1%+3.4%−22.5 pts
Year to date-12.5%+13.3%−25.8 pts
1 year-35.0%+16.6%−51.6 pts
3 years-24.8%+86.4%−111.1 pts-9.1%+23.1%
5 years-19.8%+81.9%−101.7 pts-4.3%+12.7%
10 years+4.0%+318.9%−314.8 pts+0.4%+15.4%

Fifteen years at a glance

Fiscal years 2011 to 2025 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$4.52M

Net income

-$4.70M

EPS, diluted

$0.00

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Provectus Biopharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Provectus Biopharmaceuticals

Pharmaceutical Preparations

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company that develops immunotherapy medicines for various diseases. The company's drug candidates utilize bioactive, synthetic, pharmaceutical-grade rose bengal sodium, a small molecule within the halogenated xanthenes class. Its clinical programs focus on oncology via intratumoral administration, dermatology through topical formulations, and ophthalmology. Primary investigational candidates include PV-10 for cancer indications such as melanoma and liver cancers, and PH-10 for skin conditions like psoriasis and atopic dermatitis. Provectus conducts clinical trials, expanded access programs, and non-clinical research.

Company profile, executives and history

Provectus Biopharmaceuticals stock: common questions

What is Provectus Biopharmaceuticals's stock price?

PVCT closed at $0.05 on Oct 19, 2026, up 0.39% on the day.

What is Provectus Biopharmaceuticals's market cap?

Provectus Biopharmaceuticals was worth $20.55M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is PVCT's P/E ratio?

Provectus Biopharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS $0.00), so it has no meaningful P/E ratio.

How much revenue does Provectus Biopharmaceuticals make?

Provectus Biopharmaceuticals reported revenue of $336.11K for fiscal 2025, down 45.5% from a year earlier.

Does Provectus Biopharmaceuticals pay a dividend?

No. Provectus Biopharmaceuticals has not paid a cash dividend over the last twelve months.

How has PVCT stock performed over the past year?

Including dividends, PVCT returned -35.0% over the past year, against +16.6% for the S&P 500.

Who are Provectus Biopharmaceuticals's competitors?

Companies most similar to Provectus Biopharmaceuticals by business, industry and size include INO, ALLR, LIPO, VCNX, RLYB.

See a number that looks wrong?